Cross-Presenting XCR1<sup>+</sup> Dendritic Cells as Targets for Cancer Immunotherapy
The use of dendritic cells (DCs) to generate effective anti-tumor T cell immunity has garnered much attention over the last thirty-plus years. Despite this, limited clinical benefit has been demonstrated thus far. There has been a revival of interest in DC-based treatment strategies following the re...
Main Authors: | Katherine M. Audsley, Alison M. McDonnell, Jason Waithman |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-02-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/9/3/565 |
Similar Items
-
Structure-Function Relationship of XCL1 Used for in vivo Targeting of Antigen Into XCR1+ Dendritic Cells
by: Arthur L. Kroczek, et al.
Published: (2018-12-01) -
The role of XCR1 and its ligand XCL1 in antigen cross-presentation by murine and human dendritic cells
by: Richard A. Kroczek, et al.
Published: (2012-02-01) -
Recent Advances in Nanotechnology for Dendritic Cell-Based Immunotherapy
by: Chen Qian, et al.
Published: (2020-06-01) -
STING-activating dendritic cell-targeted nanovaccines that evoke potent antigen cross-presentation for cancer immunotherapy
by: Nguyen Thi Nguyen, et al.
Published: (2024-12-01) -
Antigen Targeting of Porcine Skin DEC205<sup>+</sup> Dendritic Cells
by: Edgar Alonso Melgoza-González, et al.
Published: (2022-04-01)